Roche chooses fifth target for Halozyme's technology
This article was originally published in Scrip
Executive Summary
Halozyme Therapeutics, a US-based biopharmaceutical company, is to receive a $4.25 million milestone payment from Roche after the Swiss company selected a fifth target under the pair's existing licensing agreement.